Clinic Trials Activities EN English | TH Thai


Comparing the toxicity profile of a d4T-based regimen as lead-in for the first 6 months versus AZT-based and TDF-based first line regimens.  This year, the study completed its 72-week follow up in 150 patients from the TRCARC and Queen Savang Vadhana Memorial Hospital.  The clinical outcomes revealed that short-term d4T use before introducing AZT caused less anemia and peripheral neuropathic signs compared to initiating treatment with AZT. Initial rise in CD4 was greatest with d4T. However, peripheral fat reduction by DEXA could be observed at 1 year after d4T discontinuation. The study concluded that a 6-month d4T lead-in therapy could be considered in patients with anemia or low baseline CD4. Analyses on stored samples to decipher the pathogenesis of mitochondrial toxicity and neuropathy are ongoing. The study is funded by the Thai Government Pharmaceutical Organization and the US NIH (R01 AI074554-01A1 and R01 NS063932-01).

Home | Clinical Trials | Trainings | Resources | News & Events | Staff | Contact Us | Links
Thai Red Cross AIDS Research Center 104 Tower 2, 2nd Floor Rajdumri Road Bangkok, 10330 Thailand
© 2006 All Rights Reserved